

Ontologies Classes Object Properties Data Properties Annotation Properties Individuals Datatypes Clouds

Class: Stage_4_NSCLC

Annotations (1)

- `rdfs:comment` "Stage IVA or IVB NSCLC has already spread when it is diagnosed. These cancers can be very hard to cure. Treatment options depend on where and how far the cancer has spread, whether the cancer cells have certain gene or protein changes, and your overall health. If you are in otherwise good health, treatments such as surgery, chemotherapy (chemo), targeted therapy, immunotherapy, and radiation therapy may help you live longer and make you feel better by relieving symptoms, even though they aren't likely to cure you. Other treatments, such as photodynamic therapy (PDT) or laser therapy, may also be used to help relieve symptoms. In any case, if you are going to be treated for advanced NSCLC, be sure you understand the goals of treatment before you start."

Superclasses (1)

- `Non-Small_Cell_LC`

Disjoints (688)

`'\Abraxane_(Paclitaxel_Albumin-stabilized_Nanoparticle_Formulation)_'`, `'\Afinitor_(Everolimus)_'`,
`'\Afinitor_Disperz_(Everolimus)_'`, `'\Alecensa_(Alectinib)_'`, `'\Alimta_(Pemetrexed_Disodium)_'`,
`'\Alunbrig_(Brigatinib)_'`, `'\Alymsys_(Bevacizumab)_'`, `'\Avastin_(Bevacizumab)_'`,
`'\Cyramza_(Ramucirumab)_'`, `'\Enhertu_(Fam-Trastuzumab_Deruxtecan-nxki)_'`,
`'\Etopophos_(Etoposide_Phosphate)_'`, `'\Exkivity_(Mobocertinib_Succinate)_'`, `'\Gavreto_(Pralsetinib)_'`,
`'\Gemzar_(Gemcitabine_Hydrochloride)_'`, `'\Gilotrif_(Afatinib_Dimaleate)_'`,
`'\Hycamtin_(Topotecan_Hydrochloride)_'`, `'\Imfinzi_(Durvalumab)_'`, `'\Imjudo_(Tremelimumab-actl)_'`,
`'\Infugem_(Gemcitabine_Hydrochloride)_'`, `'\Iressa_(Gefitinib)_'`, `'\Keytruda_(Pembrolizumab)_'`,
`'\Krazati_(Adagrasib)_'`, `'\Libtayo_(Cemiplimab-rwlc)_'`, `'\Lorbrena_(Lorlatinib)_'`,
`'\Lumakras_(Sotorasib)_'`, `'\Mekinist_(Trametinib_Dimethyl_Sulfoxide)_'`, `'\Mvasi_(Bevacizumab)_'`,
`'\Opdivo_(Nivolumab)_'`, `'\Portrazza_(Necitumumab)_'`, `'\Retevmo_(Selpercatinib)_'`,
`'\Rozlytrek_(Entrectinib)_'`, `'\Rybrevant_(Amivantamab-vmjw)_'`,
`'\Tabrecta_(Capmatinib_Hydrochloride)_'`, `'\Tafinlar_(Dabrafenib_Mesylate)_'`,
`'\Tagrisso_(Osimertinib_Mesylate)_'`, `'\Taxotere_(Docetaxel)_'`, `'\Tecentriq_(Atezolizumab)_'`,
`'\Tepmetko_(Tepotinib_Hydrochloride)_'`, `'\Trexall_(Methotrexate_Sodium)_'`, `'\Vizimpro_(Dacomitinib)_'`,
`'\Xalkori_(Crizotinib)_'`, `'\Yervoy_(Ipilimumab)_'`, `'\Zirabev_(Bevacizumab)_'`, `'\Zykadia_(Ceritinib)_'`,
`Adagrasib_`, `Adherence_Based_on_Socioeconomics_LC`, `Adherence_Factors_LC`, `Adverse_Reactions_ABRAX`,
`Adverse_Reactions_ADAGR`, `Adverse_Reactions_AFATI`, `Adverse_Reactions_AFINI`, `Adverse_Reactions_AFINIT`,
`Adverse_Reactions_ALECE`, `Adverse_Reactions_ALIMT`, `Adverse_Reactions_ALUNB`, `Adverse_Reactions_ALYMS`,
`Adverse_Reactions_AMIVA`, `Adverse_Reactions_ATEZO`, `Adverse_Reactions_AVAST`, `Adverse_Reactions_BRIGA`,
`Adverse_Reactions_CAPMA`, `Adverse_Reactions_CEMIP`, `Adverse_Reactions_CYRAM`,
`Adverse_Reactions_DOXOR`, `Adverse_Reactions_DURVA`, `Adverse_Reactions_ENHER`,
`Adverse_Reactions_ENTRE`, `Adverse_Reactions_ERLOT`, `Adverse_Reactions_ETOP`, `Adverse_Reactions_ETOPO`,
`Adverse_Reactions_EXKIV`, `Adverse_Reactions_GAVRE`, `Adverse_Reactions_GEFIT`, `Adverse_Reactions_GEMZA`,
`Adverse_Reactions_GILOT`, `Adverse_Reactions_HYCAM`, `Adverse_Reactions_IMFIN`, `Adverse_Reactions_IMJUD`,
`Adverse_Reactions_INFUG`, `Adverse_Reactions_IRESS`, `Adverse_Reactions_KEYTR`, `Adverse_Reactions_KRAZA`,
`Adverse_Reactions_LIBTA`, `Adverse_Reactions_LORBR`, `Adverse_Reactions_LUMAK`, `Adverse_Reactions_LURB`,
`Adverse_Reactions_MEKIN`, `Adverse_Reactions_METH`, `Adverse_Reactions_MVASI`, `Adverse_Reactions_OPDIV`,
`Adverse_Reactions_PORTR`, `Adverse_Reactions_RAMUC`, `Adverse_Reactions_RETEV`, `Adverse_Reactions_ROZLY`,
`Adverse_Reactions_RYBRE`, `Adverse_Reactions_SELPE`, `Adverse_Reactions_SOTOR`, `Adverse_Reactions_TABRE`,
`Adverse_Reactions_TAFIN`, `Adverse_Reactions_TAGRIS`, `Adverse_Reactions_TAXOT`, `Adverse_Reactions_TECEN`,
`Adverse_Reactions_TEPME`, `Adverse_Reactions_TOPO`, `Adverse_Reactions_TRAME`, `Adverse_Reactions_TREME`,
`Adverse_Reactions_TREXA`, `Adverse_Reactions_VINOR`, `Adverse_Reactions_VIZIM`, `Adverse_Reactions_XALKO`,
`Adverse_Reactions_YERVO`, `Adverse_Reactions_ZIRAB`, `Adverse_Reactions_ZYKAD`, `Afatinib_Dimaleate_`, `Age`,
`Air_Pollution`, `Amivantamab-vmjw_`, `Atezolizumab_`, `Behavioral_Factors_LC`, `Beta_Carotene_Supplements_LC`,
`Bio_Sensors_LC`, `Biological_Effects_LC`, `Breathalyzer_LC`, `Breathing_LC`, `Brigatinib_`,
`Capmatinib_Hydrochloride_`, `Causes_and_Risks_LC`, `Cemiplimab-rwlc_`, `Chemical_Sensors_LC`,
`Choosing_Quality_of_Life_-_Reasons_People_Forego_Treatment`, `Choosing_Survival_-_`
`_Deciding_to_Undergo_Treatment`, `Complications_LC`, `Contraindications_ABRAX`, `Contraindications_ADAGR`,
`Contraindications_AFATI`, `Contraindications_AFINI`, `Contraindications_AFINIT`, `Contraindications_ALECE`,
`Contraindications_ALIMT`, `Contraindications_ALUNB`, `Contraindications_ALYMS`, `Contraindications_AMIVA`,

Contraindications_ATEZO, Contraindications_AVAST, Contraindications_BRIGA, Contraindications_CAPMA, Contraindications_CEMIP, Contraindications_CYRAM, Contraindications_DOXOR, Contraindications_DURVA, Contraindications_ENHER, Contraindications_ENTRE, Contraindications_ERLOT, Contraindications_ETOP, Contraindications_ETOPO, Contraindications_EXKIV, Contraindications_GAVRE, Contraindications_GEFIT, Contraindications_GEMZA, Contraindications_GILOT, Contraindications_HYCAM, Contraindications_IMFIN, Contraindications_IMJUD, Contraindications_INFUG, Contraindications_IRESS, Contraindications_KEYTR, Contraindications_KRAZA, Contraindications_LIBTA, Contraindications_LORBR, Contraindications_LUMAK, Contraindications_LURB, Contraindications_MEKIN, Contraindications_METH, Contraindications_MVASI, Contraindications_OPDIV, Contraindications_PORTR, Contraindications_RAMUC, Contraindications_RETEV, Contraindications_ROZLY, Contraindications_RYBRE, Contraindications_SELPE, Contraindications_SOTOR, Contraindications_TABRE, Contraindications_TAFIN, Contraindications_TAGRIS, Contraindications_TAXOT, Contraindications_TECEN, Contraindications_TEPME, Contraindications_TOPO, Contraindications_TRAME, Contraindications_TREME, Contraindications_TREXA, Contraindications_VINOR, Contraindications_VIZIM, Contraindications_XALKO, Contraindications_YERVO, Contraindications_ZIRAB, Contraindications_ZYKAD, Cultural_Beliefs_and_Perceptions, Cultural_LC, Degrees_of_Smoking_LC, Demographic_Factors_LC, Diet_LC, Disparities_in_Incidence, Dosage_and_Administration_ABRAX, Dosage_and_Administration_ADAGR, Dosage_and_Administration_AFATI, Dosage_and_Administration_AFINI, Dosage_and_Administration_AFINIT, Dosage_and_Administration_ALECE, Dosage_and_Administration_ALIMT, Dosage_and_Administration_ALUNB, Dosage_and_Administration_ALYMS, Dosage_and_Administration_AMIVA, Dosage_and_Administration_ATEZO, Dosage_and_Administration_AVAST, Dosage_and_Administration_BRIGA, Dosage_and_Administration_CAPMA, Dosage_and_Administration_CEMIP, Dosage_and_Administration_CYRAM, Dosage_and_Administration_DOXOR, Dosage_and_Administration_DURVA, Dosage_and_Administration_ENHER, Dosage_and_Administration_ENTRE, Dosage_and_Administration_ERLOT, Dosage_and_Administration_ETOP, Dosage_and_Administration_ETOPO, Dosage_and_Administration_EXKIV, Dosage_and_Administration_GAVRE, Dosage_and_Administration_GEFIT, Dosage_and_Administration_GEMZA, Dosage_and_Administration_GILOT, Dosage_and_Administration_HYCAM, Dosage_and_Administration_IMFIN, Dosage_and_Administration_IMJUD, Dosage_and_Administration_INFUG, Dosage_and_Administration_IRESS, Dosage_and_Administration_KEYTR, Dosage_and_Administration_KRAZA, Dosage_and_Administration_LIBTA, Dosage_and_Administration_LORBR, Dosage_and_Administration_LUMAK, Dosage_and_Administration_LURB, Dosage_and_Administration_MEKIN, Dosage_and_Administration_METH, Dosage_and_Administration_MVASI, Dosage_and_Administration_OPDIV, Dosage_and_Administration_PORTR, Dosage_and_Administration_RAMUC, Dosage_and_Administration_RETEV, Dosage_and_Administration_ROZLY, Dosage_and_Administration_RYBRE, Dosage_and_Administration_SELPE, Dosage_and_Administration_SOTOR, Dosage_and_Administration_TABRE, Dosage_and_Administration_TAFIN, Dosage_and_Administration_TAGRIS, Dosage_and_Administration_TAXOT, Dosage_and_Administration_TECEN, Dosage_and_Administration_TEPME, Dosage_and_Administration_TOPO, Dosage_and_Administration_TRAME, Dosage_and_Administration_TREME, Dosage_and_Administration_TREXA, Dosage_and_Administration_VINOR, Dosage_and_Administration_VIZIM, Dosage_and_Administration_XALKO, Dosage_and_Administration_YERVO, Dosage_and_Administration_ZIRAB, Dosage_and_Administration_ZYKAD, Dosage_Forms_and_Strengths_ABRAX, Dosage_Forms_and_Strengths_ADAGR, Dosage_Forms_and_Strengths_AFATI, Dosage_Forms_and_Strengths_AFINI, Dosage_Forms_and_Strengths_AFINIT, Dosage_Forms_and_Strengths_ALECE, Dosage_Forms_and_Strengths_ALIMT, Dosage_Forms_and_Strengths_ALUNB, Dosage_Forms_and_Strengths_ALYMS, Dosage_Forms_and_Strengths_AMIVA, Dosage_Forms_and_Strengths_ATEZO, Dosage_Forms_and_Strengths_AVAST, Dosage_Forms_and_Strengths_BRIGA, Dosage_Forms_and_Strengths_CAPMA, Dosage_Forms_and_Strengths_CEMIP, Dosage_Forms_and_Strengths_CYRAM, Dosage_Forms_and_Strengths_DOXOR, Dosage_Forms_and_Strengths_DURVA, Dosage_Forms_and_Strengths_ENHER, Dosage_Forms_and_Strengths_ENTRE, Dosage_Forms_and_Strengths_ERLOT, Dosage_Forms_and_Strengths_ETOP, Dosage_Forms_and_Strengths_ETOPO, Dosage_Forms_and_Strengths_EXKIV, Dosage_Forms_and_Strengths_GAVRE, Dosage_Forms_and_Strengths_GEFIT, Dosage_Forms_and_Strengths_GEMZA, Dosage_Forms_and_Strengths_GILOT, Dosage_Forms_and_Strengths_HYCAM, Dosage_Forms_and_Strengths_IMFIN, Dosage_Forms_and_Strengths_IMJUD, Dosage_Forms_and_Strengths_INFUG, Dosage_Forms_and_Strengths_IRESS, Dosage_Forms_and_Strengths_KEYTR, Dosage_Forms_and_Strengths_KRAZA, Dosage_Forms_and_Strengths_LIBTA, Dosage_Forms_and_Strengths_LORBR, Dosage_Forms_and_Strengths_LUMAK, Dosage_Forms_and_Strengths_LURB, Dosage_Forms_and_Strengths_MEKIN, Dosage_Forms_and_Strengths_METH, Dosage_Forms_and_Strengths_MVASI, Dosage_Forms_and_Strengths_OPDIV, Dosage_Forms_and_Strengths_PORTR, Dosage_Forms_and_Strengths_RAMUC, Dosage_Forms_and_Strengths_RETEV, Dosage_Forms_and_Strengths_ROZLY, Dosage_Forms_and_Strengths_RYBRE, Dosage_Forms_and_Strengths_SELPE, Dosage_Forms_and_Strengths_SOTOR, Dosage_Forms_and_Strengths_TABRE, Dosage_Forms_and_Strengths_TAFIN, Dosage_Forms_and_Strengths_TAGRIS, Dosage_Forms_and_Strengths_TAXOT, Dosage_Forms_and_Strengths_TECEN,

Dosage_Forms_and_Strengths_TEPME, Dosage_Forms_and_Strengths_TOPO,
 Dosage_Forms_and_Strengths_TRAME, Dosage_Forms_and_Strengths_TREME,
 Dosage_Forms_and_Strengths_TREXA, Dosage_Forms_and_Strengths_VINOR,
 Dosage_Forms_and_Strengths_VIZIM, Dosage_Forms_and_Strengths_XALKO,
 Dosage_Forms_and_Strengths_YERVO, Dosage_Forms_and_Strengths_ZIRAB,
 Dosage_Forms_and_Strengths_ZYKAD, Doxorubicin_Hydrochloride_, Drug_Interactions_ABRAX,
 Drug_Interactions_ADAGR, Drug_Interactions_AFATI, Drug_Interactions_AFINI, Drug_Interactions_AFINIT,
 Drug_Interactions_ALECE, Drug_Interactions_ALIMT, Drug_Interactions_ALUNB, Drug_Interactions_ALYMS,
 Drug_Interactions_AMIVA, Drug_Interactions_ATEZO, Drug_Interactions_AVAST, Drug_Interactions_BRIGA,
 Drug_Interactions_CAPMA, Drug_Interactions_CEMIP, Drug_Interactions_CYRAM, Drug_Interactions_DOXOR,
 Drug_Interactions_DURVA, Drug_Interactions_ENHER, Drug_Interactions_ENTRE, Drug_Interactions_ERLOT,
 Drug_Interactions_ETOP, Drug_Interactions_ETOPO, Drug_Interactions_EXKIV, Drug_Interactions_GAVRE,
 Drug_Interactions_GEFIT, Drug_Interactions_GEMZA, Drug_Interactions_GILOT, Drug_Interactions_HYCAM,
 Drug_Interactions_IMFIN, Drug_Interactions_IMJUD, Drug_Interactions_INFUG, Drug_Interactions_IRESS,
 Drug_Interactions_KEYTR, Drug_Interactions_KRAZA, Drug_Interactions_LIBTA, Drug_Interactions_LORBR,
 Drug_Interactions_LUMAK, Drug_Interactions_LURB, Drug_Interactions_MEKIN, Drug_Interactions_METH,
 Drug_Interactions_MVASI, Drug_Interactions_OPDIV, Drug_Interactions_PORTR, Drug_Interactions_RAMUC,
 Drug_Interactions_RETEV, Drug_Interactions_ROZLY, Drug_Interactions_RYBRE, Drug_Interactions_SELPE,
 Drug_Interactions_SOTOR, Drug_Interactions_TABRE, Drug_Interactions_TAFIN, Drug_Interactions_TAGRIS,
 Drug_Interactions_TAXOT, Drug_Interactions_TECEN, Drug_Interactions_TEPME, Drug_Interactions_TOPO,
 Drug_Interactions_TRAME, Drug_Interactions_TREME, Drug_Interactions_TREXA, Drug_Interactions_VINOR,
 Drug_Interactions_VIZIM, Drug_Interactions_XALKO, Drug_Interactions_YERVO, Drug_Interactions_ZIRAB,
 Drug_Interactions_ZYKAD, Durvalumab_, E-Cigarettes_LC, Electronic_Sensors_LC, Emotions_LC,
 End_of_Life_Decisions, Entrectinib_, Environmental_Factors_LC, Enzymatic_Sensors_LC,
 Erlotinib_Hydrochloride_, Etoposide_, Exercise_LC, Extensive_Stage_SCLC, Family_History_LC, Gefitinib_,
 Genomic_Sequencing_LC, Geographical_Location, Habits_LC, HIV_Infection_LC, Immunosensors_LC,
 Increased_Susceptibility_LC, Indications_and_Usage_ABRAX, Indications_and_Usage_ADAGR,
 Indications_and_Usage_AFATI, Indications_and_Usage_AFINI, Indications_and_Usage_AFINIT,
 Indications_and_Usage_ALECE, Indications_and_Usage_ALIMT, Indications_and_Usage_ALUNB,
 Indications_and_Usage_ALYMS, Indications_and_Usage_AMIVA, Indications_and_Usage_ATEZO,
 Indications_and_Usage_AVAST, Indications_and_Usage_BRIGA, Indications_and_Usage_CAPMA,
 Indications_and_Usage_CEMIP, Indications_and_Usage_CYRAM, Indications_and_Usage_DOXOR,
 Indications_and_Usage_DURVA, Indications_and_Usage_ENHER, Indications_and_Usage_ENTRE,
 Indications_and_Usage_ERLOT, Indications_and_Usage_ETOP, Indications_and_Usage_ETOPO,
 Indications_and_Usage_EXKIV, Indications_and_Usage_GAVRE, Indications_and_Usage_GEFIT,
 Indications_and_Usage_GEMZA, Indications_and_Usage_GILOT, Indications_and_Usage_HYCAM,
 Indications_and_Usage_IMFIN, Indications_and_Usage_IMJUD, Indications_and_Usage_INFUG,
 Indications_and_Usage_IRESS, Indications_and_Usage_KEYTR, Indications_and_Usage_KRAZA,
 Indications_and_Usage_LIBTA, Indications_and_Usage_LORBR, Indications_and_Usage_LUMAK,
 Indications_and_Usage_LURB, Indications_and_Usage_MEKIN, Indications_and_Usage_METH,
 Indications_and_Usage_MVASI, Indications_and_Usage_OPDIV, Indications_and_Usage_PORTR,
 Indications_and_Usage_RAMUC, Indications_and_Usage_RETEV, Indications_and_Usage_ROZLY,
 Indications_and_Usage_RYBRE, Indications_and_Usage_SELPE, Indications_and_Usage_SOTOR,
 Indications_and_Usage_TABRE, Indications_and_Usage_TAFIN, Indications_and_Usage_TAGRIS,
 Indications_and_Usage_TAXOT, Indications_and_Usage_TECEN, Indications_and_Usage_TEPME,
 Indications_and_Usage_TOPO, Indications_and_Usage_TRAME, Indications_and_Usage_TREME,
 Indications_and_Usage_TREXA, Indications_and_Usage_VINOR, Indications_and_Usage_VIZIM,
 Indications_and_Usage_XALKO, Indications_and_Usage_YERVO, Indications_and_Usage_ZIRAB,
 Indications_and_Usage_ZYKAD, Limited_Stage_SCLC, Living_with_LC_LC, Location_LC, Lurbinectedin_,
 Marijuna_Smoking_LC, Medications_LC, Methotrexate_Sodium_, Never-Smokers_LC, Non-
 Small_Cell_LC_NSCLC, Non-Small_Cell_Lung_Cancer, Non-Small_Cell_Medication_LC_, Non-Smokers_LC, Non-
 Smokers_NSCLC, Non-Smokers_SCLC, Nutrition_LC, Occupational_Exposure,
 Physical_Activity_For_Mitigation_of_LC, Physical_Activity_For_Prevention_Of_LC, Preventative_habits_LC,
 Quitting/Not_Smoking_LC, Racial/Ethnic, Radiation_Exposure_LC, Ramucirumab_, Recurring_LC_NSCLC,
 Recurring_LC_SCLC, Rural_LC, Second-hand_Smoke_LC, Secondhand_Smoke_LC, Selpercatinib_,
 Sensor_Factors_LC, Size_of_the_community_LC, Sleep_LC, Small_Cell_LC, Small_Cell_LC_SCLC,
 Small_Cell_Lung_Cancer, Small_Cell_Medication_LC_, Smoke_LC, Smokers_LC, Smokers_NSCLC,
 Smokers_SCLC, Smoking_LC, Smoking_Marijuana_LC, Smoking_Other_Drugs_LC, Smoking_Tobacco_LC,
 Socioeconomics_LC, Sotorasib_, Stage_0_NSCLC, Stage_1_NSCLC, Stage_1_SCLC, Stage_2_NSCLC,
 Stage_3A_NSCLC, Stage_3B_NSCLC, **Stage_4_NSCLC**, Support_Groups_LC, Symptoms_and_Tests_LC,
 Symptoms_NSC, Symptoms_SC, Tests_NSC, Tests_SC, Tobacco_Smoking, Tobacco_Smoking_LC,
 Topotecan_Hydrochloride_, Tramentinib_Dimethyl_Sulfoxide, Treatment_Regimens_LC, Tremelimumab-actl_,
 Urban_LC, Use_in_Specific_Populations_ABRAX, Use_in_Specific_Populations_ADAGR,
 Use_in_Specific_Populations_AFATI, Use_in_Specific_Populations_AFINI, Use_in_Specific_Populations_AFINIT,
 Use_in_Specific_Populations_ALECE, Use_in_Specific_Populations_ALIMT, Use_in_Specific_Populations_ALUNB,

Use_in_Specific_Populations_ALYMS, Use_in_Specific_Populations_AMIVA, Use_in_Specific_Populations_ATEZO, Use_in_Specific_Populations_AVAST, Use_in_Specific_Populations_BRIGA, Use_in_Specific_Populations_CAPMA, Use_in_Specific_Populations_CEMIP, Use_in_Specific_Populations_CYRAM, Use_in_Specific_Populations_DOXOR, Use_in_Specific_Populations_DURVA, Use_in_Specific_Populations_ENHER, Use_in_Specific_Populations_ENTRE, Use_in_Specific_Populations_ERLOT, Use_in_Specific_Populations_ETOP, Use_in_Specific_Populations_ETOPO, Use_in_Specific_Populations_EXKIV, Use_in_Specific_Populations_GAVRE, Use_in_Specific_Populations_GEFIT, Use_in_Specific_Populations_GEMZA, Use_in_Specific_Populations_GILOT, Use_in_Specific_Populations_HYCAM, Use_in_Specific_Populations_IMFIN, Use_in_Specific_Populations_IMJUD, Use_in_Specific_Populations_INFUG, Use_in_Specific_Populations_IRESS, Use_in_Specific_Populations_KEYTR, Use_in_Specific_Populations_KRAZA, Use_in_Specific_Populations_LIBTA, Use_in_Specific_Populations_LORBR, Use_in_Specific_Populations_LUMAK, Use_in_Specific_Populations_LURB, Use_in_Specific_Populations_MEKIN, Use_in_Specific_Populations_METH, Use_in_Specific_Populations_MVASI, Use_in_Specific_Populations_OPDIV, Use_in_Specific_Populations_PORTR, Use_in_Specific_Populations_RAMUC, Use_in_Specific_Populations_RETEV, Use_in_Specific_Populations_ROZLY, Use_in_Specific_Populations_RYBRE, Use_in_Specific_Populations_SELPE, Use_in_Specific_Populations_SOTOR, Use_in_Specific_Populations_TABRE, Use_in_Specific_Populations_TAFIN, Use_in_Specific_Populations_TAGRIS, Use_in_Specific_Populations_TAXOT, Use_in_Specific_Populations_TECEN, Use_in_Specific_Populations_TEPME, Use_in_Specific_Populations_TOPO, Use_in_Specific_Populations_TRAME, Use_in_Specific_Populations_TREME, Use_in_Specific_Populations_TREXA, Use_in_Specific_Populations_VINOR, Use_in_Specific_Populations_VIZIM, Use_in_Specific_Populations_XALKO, Use_in_Specific_Populations_YERVO, Use_in_Specific_Populations_ZIRAB, Use_in_Specific_Populations_ZYKAD, Vinorelbine_Tartrate_, Warnings_and_Precautions_ABRAX, Warnings_and_Precautions_ADAGR, Warnings_and_Precautions_AFATI, Warnings_and_Precautions_AFINI, Warnings_and_Precautions_AFINIT, Warnings_and_Precautions_ALECE, Warnings_and_Precautions_ALIMT, Warnings_and_Precautions_ALUNB, Warnings_and_Precautions_ALYMS, Warnings_and_Precautions_AMIVA, Warnings_and_Precautions_ATEZO, Warnings_and_Precautions_AVAST, Warnings_and_Precautions_BRIGA, Warnings_and_Precautions_CAPMA, Warnings_and_Precautions_CEMIP, Warnings_and_Precautions_CYRAM, Warnings_and_Precautions_DOXOR, Warnings_and_Precautions_DURVA, Warnings_and_Precautions_ENHER, Warnings_and_Precautions_ENTRE, Warnings_and_Precautions_ERLOT, Warnings_and_Precautions_ETOP, Warnings_and_Precautions_ETOPO, Warnings_and_Precautions_EXKIV, Warnings_and_Precautions_GAVRE, Warnings_and_Precautions_GEFIT, Warnings_and_Precautions_GEMZA, Warnings_and_Precautions_GILOT, Warnings_and_Precautions_HYCAM, Warnings_and_Precautions_IMFIN, Warnings_and_Precautions_IMJUD, Warnings_and_Precautions_INFUG, Warnings_and_Precautions_IRESS, Warnings_and_Precautions_KEYTR, Warnings_and_Precautions_KRAZA, Warnings_and_Precautions_LIBTA, Warnings_and_Precautions_LORBR, Warnings_and_Precautions_LUMAK, Warnings_and_Precautions_LURB, Warnings_and_Precautions_MEKIN, Warnings_and_Precautions_METH, Warnings_and_Precautions_MVASI, Warnings_and_Precautions_OPDIV, Warnings_and_Precautions_PORTR, Warnings_and_Precautions_RAMUC, Warnings_and_Precautions_RETEV, Warnings_and_Precautions_ROZLY, Warnings_and_Precautions_RYBRE, Warnings_and_Precautions_SELPE, Warnings_and_Precautions_SOTOR, Warnings_and_Precautions_TABRE, Warnings_and_Precautions_TAFIN, Warnings_and_Precautions_TAGRIS, Warnings_and_Precautions_TAXOT, Warnings_and_Precautions_TECEN, Warnings_and_Precautions_TEPME, Warnings_and_Precautions_TOPO, Warnings_and_Precautions_TRAME, Warnings_and_Precautions_TREME, Warnings_and_Precautions_TREXA, Warnings_and_Precautions_VINOR, Warnings_and_Precautions_VIZIM, Warnings_and_Precautions_XALKO, Warnings_and_Precautions_YERVO, Warnings_and_Precautions_ZIRAB, Warnings_and_Precautions_ZYKAD

OWL HTML inside